chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 48.0
Sex: F
Vaccine: FLU4
Symptoms: Dizziness, Hot flush
Clinical narrative: She felt very anxious beforehand and got dizzy with hot flashes after receiving the vaccine. She sat on the floor afterwards and drank some orange juice and I gave her a cold pack for her neck and a fan to cool her off. After about 30 minutes,  her daughter came to pick her up. She was feeling a little better and her daughter drove her home.
Age: 50.0
Sex: M
Vaccine: VARZOS
Symptoms: Rash
Clinical narrative: RASH- which started about 48h after vaccination and spread, started to improve 7-10d post vaccination
Age: 77.0
Sex: F
Vaccine: FLU3
Symptoms: Injection site pain
Clinical narrative: I have pain at the injection site on my left arm. It is almost 3 months later.  I feel it mostly at night if I roll over onto that arm but I also feel it sometimes during the day.  I can "bear" it but thought I should report this as an adverse effect.
Age: 67.0
Sex: F
Vaccine: VARZOS
Symptoms: Blister, Chills, Facial pain, Fatigue, Lip blister
Clinical narrative: Less than 24 hours after shot, I will briefly descirbe adverse reactions as follows: 1.  shiver which turned into shaking uncontrollably until I could grab my hand with another and steady to take ibuprofen 2.  extreme exhaustion 3.  severe blisters inside mouth, gums, lips approx. 4 days after injection 4.  blisters outside of lips same as above 5.  severe face pain and headache before blisters appeared 3 days after injection 6. 6 days after injection, diagnosed with severe read sore throat, severe left ear infection, given antibiotics 5.  blister on left side of face ( appears to be shingles) No illnesses known more than 60 days prior to injection--My general health is very good and I am very active.
Age: 67.0
Sex: F
Vaccine: VARZOS
Symptoms: Oral mucosal blistering, Streptococcus test negative, Tremor
Clinical narrative: Less than 24 hours after shot, I will briefly descirbe adverse reactions as follows: 1.  shiver which turned into shaking uncontrollably until I could grab my hand with another and steady to take ibuprofen 2.  extreme exhaustion 3.  severe blisters inside mouth, gums, lips approx. 4 days after injection 4.  blisters outside of lips same as above 5.  severe face pain and headache before blisters appeared 3 days after injection 6. 6 days after injection, diagnosed with severe read sore throat, severe left ear infection, given antibiotics 5.  blister on left side of face ( appears to be shingles) No illnesses known more than 60 days prior to injection--My general health is very good and I am very active.
Age: 70.0
Sex: F
Vaccine: VARZOS
Symptoms: Pain, Rash, Rash pruritic
Clinical narrative: Progressive, transient rash across mid-upper abdomen, right leg and trunk to upper breasts, one day after vaccine admin. Transient rash beginning on back, additionally, with itchiness. Use of diphenhydramine, rash persisted to spread to inner arms after one hour. Non feverish, yet generalized aches.
Age: 72.0
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Arthralgia, Blood test, Injection site pain, Joint stiffness, Laboratory test
Clinical narrative: autoimmune reaction; rheumatoid arthritis diagnosis; knee joint pain/joints in body were painful; bilateral shoulder pain; joints in body were swollen; left arm soreness/right arm soreness/hand pain/finger pain; injection site pain; This case was reported by a consumer via call center representative and described the occurrence of autoimmune disorder in a 72-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 16th April 2018, the patient received the 1st dose of Shingrix (intramuscular). On 16th April 2018, 5 hrs after receiving Shingrix, the patient experienced injection site pain. On 17th April 2018, the patient experienced pain in arm. On 23rd April 2018, the patient experienced autoimmune disorder (serious criteria GSK medically significant), rheumatoid arthritis (serious criteria GSK medically significant), knee pain, shoulder pain and swollen joints. The patient was treated with hydrocortisone (Cortisone (Hydrocortisone)). On an unknown date, the outcome of the autoimmune disorder, rheumatoid arthritis, knee pain, pain in arm and shoulder pain were not recovered/not resolved and the outcome of the injection site pain was recovered/resolved and the outcome of the swollen joints was recovering/resolving.   It was unknown if the reporter considered the autoimmune disorder, rheumatoid arthritis, knee pain, injection site pain, pain in arm, shoulder pain and swollen joints to be related to Shingrix.  Additional details were provided as follows: The patient experienced injection site pain in the left upper arm. The next day after receiving Shingrix, the patient experienced arm soreness in both the left and right arms. One week after receiving Shingrix,  the patient began to experience bilateral shoulder pain.  The patient also experienced pain in hands and fingers. It was reported that all the joints in her body were swollen and painful. The patient experienced knee pain. The patient underwent an MRI of the cervical and thoracic spine which were negative. The patient was seen by a neurologist who reported there was no significant test abnormality. The patient was seen by an orthopedist and X-rays were negative. The patient was prescribed cortisone in the hands, which helped for a short time, but then returned.  The patient was then diagnosed with an unknown autoimmune disorder and rheumatoid arthritis. The reporter consented to follow up.      Lab Comments: on an unknwn date, MRI of the cervical and thoracic spine and MRI were performed.
Age: 72.0
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Musculoskeletal pain, Musculoskeletal stiffness, Neuralgic amyotrophy, Pain in extremity, Peripheral swelling
Clinical narrative: autoimmune reaction; rheumatoid arthritis diagnosis; knee joint pain/joints in body were painful; bilateral shoulder pain; joints in body were swollen; left arm soreness/right arm soreness/hand pain/finger pain; injection site pain; This case was reported by a consumer via call center representative and described the occurrence of autoimmune disorder in a 72-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 16th April 2018, the patient received the 1st dose of Shingrix (intramuscular). On 16th April 2018, 5 hrs after receiving Shingrix, the patient experienced injection site pain. On 17th April 2018, the patient experienced pain in arm. On 23rd April 2018, the patient experienced autoimmune disorder (serious criteria GSK medically significant), rheumatoid arthritis (serious criteria GSK medically significant), knee pain, shoulder pain and swollen joints. The patient was treated with hydrocortisone (Cortisone (Hydrocortisone)). On an unknown date, the outcome of the autoimmune disorder, rheumatoid arthritis, knee pain, pain in arm and shoulder pain were not recovered/not resolved and the outcome of the injection site pain was recovered/resolved and the outcome of the swollen joints was recovering/resolving.   It was unknown if the reporter considered the autoimmune disorder, rheumatoid arthritis, knee pain, injection site pain, pain in arm, shoulder pain and swollen joints to be related to Shingrix.  Additional details were provided as follows: The patient experienced injection site pain in the left upper arm. The next day after receiving Shingrix, the patient experienced arm soreness in both the left and right arms. One week after receiving Shingrix,  the patient began to experience bilateral shoulder pain.  The patient also experienced pain in hands and fingers. It was reported that all the joints in her body were swollen and painful. The patient experienced knee pain. The patient underwent an MRI of the cervical and thoracic spine which were negative. The patient was seen by a neurologist who reported there was no significant test abnormality. The patient was seen by an orthopedist and X-rays were negative. The patient was prescribed cortisone in the hands, which helped for a short time, but then returned.  The patient was then diagnosed with an unknown autoimmune disorder and rheumatoid arthritis. The reporter consented to follow up.      Lab Comments: on an unknwn date, MRI of the cervical and thoracic spine and MRI were performed.
Age: 72.0
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Rheumatoid arthritis, Small fibre neuropathy, Spinal X-ray, Swelling, Weight decreased
Clinical narrative: autoimmune reaction; rheumatoid arthritis diagnosis; knee joint pain/joints in body were painful; bilateral shoulder pain; joints in body were swollen; left arm soreness/right arm soreness/hand pain/finger pain; injection site pain; This case was reported by a consumer via call center representative and described the occurrence of autoimmune disorder in a 72-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 16th April 2018, the patient received the 1st dose of Shingrix (intramuscular). On 16th April 2018, 5 hrs after receiving Shingrix, the patient experienced injection site pain. On 17th April 2018, the patient experienced pain in arm. On 23rd April 2018, the patient experienced autoimmune disorder (serious criteria GSK medically significant), rheumatoid arthritis (serious criteria GSK medically significant), knee pain, shoulder pain and swollen joints. The patient was treated with hydrocortisone (Cortisone (Hydrocortisone)). On an unknown date, the outcome of the autoimmune disorder, rheumatoid arthritis, knee pain, pain in arm and shoulder pain were not recovered/not resolved and the outcome of the injection site pain was recovered/resolved and the outcome of the swollen joints was recovering/resolving.   It was unknown if the reporter considered the autoimmune disorder, rheumatoid arthritis, knee pain, injection site pain, pain in arm, shoulder pain and swollen joints to be related to Shingrix.  Additional details were provided as follows: The patient experienced injection site pain in the left upper arm. The next day after receiving Shingrix, the patient experienced arm soreness in both the left and right arms. One week after receiving Shingrix,  the patient began to experience bilateral shoulder pain.  The patient also experienced pain in hands and fingers. It was reported that all the joints in her body were swollen and painful. The patient experienced knee pain. The patient underwent an MRI of the cervical and thoracic spine which were negative. The patient was seen by a neurologist who reported there was no significant test abnormality. The patient was seen by an orthopedist and X-rays were negative. The patient was prescribed cortisone in the hands, which helped for a short time, but then returned.  The patient was then diagnosed with an unknown autoimmune disorder and rheumatoid arthritis. The reporter consented to follow up.      Lab Comments: on an unknwn date, MRI of the cervical and thoracic spine and MRI were performed.
Age: 72.0
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: X-ray limb
Clinical narrative: autoimmune reaction; rheumatoid arthritis diagnosis; knee joint pain/joints in body were painful; bilateral shoulder pain; joints in body were swollen; left arm soreness/right arm soreness/hand pain/finger pain; injection site pain; This case was reported by a consumer via call center representative and described the occurrence of autoimmune disorder in a 72-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 16th April 2018, the patient received the 1st dose of Shingrix (intramuscular). On 16th April 2018, 5 hrs after receiving Shingrix, the patient experienced injection site pain. On 17th April 2018, the patient experienced pain in arm. On 23rd April 2018, the patient experienced autoimmune disorder (serious criteria GSK medically significant), rheumatoid arthritis (serious criteria GSK medically significant), knee pain, shoulder pain and swollen joints. The patient was treated with hydrocortisone (Cortisone (Hydrocortisone)). On an unknown date, the outcome of the autoimmune disorder, rheumatoid arthritis, knee pain, pain in arm and shoulder pain were not recovered/not resolved and the outcome of the injection site pain was recovered/resolved and the outcome of the swollen joints was recovering/resolving.   It was unknown if the reporter considered the autoimmune disorder, rheumatoid arthritis, knee pain, injection site pain, pain in arm, shoulder pain and swollen joints to be related to Shingrix.  Additional details were provided as follows: The patient experienced injection site pain in the left upper arm. The next day after receiving Shingrix, the patient experienced arm soreness in both the left and right arms. One week after receiving Shingrix,  the patient began to experience bilateral shoulder pain.  The patient also experienced pain in hands and fingers. It was reported that all the joints in her body were swollen and painful. The patient experienced knee pain. The patient underwent an MRI of the cervical and thoracic spine which were negative. The patient was seen by a neurologist who reported there was no significant test abnormality. The patient was seen by an orthopedist and X-rays were negative. The patient was prescribed cortisone in the hands, which helped for a short time, but then returned.  The patient was then diagnosed with an unknown autoimmune disorder and rheumatoid arthritis. The reporter consented to follow up.      Lab Comments: on an unknwn date, MRI of the cervical and thoracic spine and MRI were performed.
Age: 72.0
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Arthralgia, Autoimmune disorder, Injection site pain, Joint swelling, Laboratory test normal
Clinical narrative: autoimmune reaction; rheumatoid arthritis diagnosis; knee joint pain/joints in body were painful; bilateral shoulder pain; joints in body were swollen; left arm soreness/right arm soreness/hand pain/finger pain; injection site pain; This case was reported by a consumer via call center representative and described the occurrence of autoimmune disorder in a 72-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 16th April 2018, the patient received the 1st dose of Shingrix (intramuscular). On 16th April 2018, 5 hrs after receiving Shingrix, the patient experienced injection site pain. On 17th April 2018, the patient experienced pain in arm. On 23rd April 2018, the patient experienced autoimmune disorder (serious criteria GSK medically significant), rheumatoid arthritis (serious criteria GSK medically significant), knee pain, shoulder pain and swollen joints. The patient was treated with hydrocortisone (Cortisone (Hydrocortisone)). On an unknown date, the outcome of the autoimmune disorder, rheumatoid arthritis, knee pain, pain in arm and shoulder pain were not recovered/not resolved and the outcome of the injection site pain was recovered/resolved and the outcome of the swollen joints was recovering/resolving.   It was unknown if the reporter considered the autoimmune disorder, rheumatoid arthritis, knee pain, injection site pain, pain in arm, shoulder pain and swollen joints to be related to Shingrix.  Additional details were provided as follows: The patient experienced injection site pain in the left upper arm. The next day after receiving Shingrix, the patient experienced arm soreness in both the left and right arms. One week after receiving Shingrix,  the patient began to experience bilateral shoulder pain.  The patient also experienced pain in hands and fingers. It was reported that all the joints in her body were swollen and painful. The patient experienced knee pain. The patient underwent an MRI of the cervical and thoracic spine which were negative. The patient was seen by a neurologist who reported there was no significant test abnormality. The patient was seen by an orthopedist and X-rays were negative. The patient was prescribed cortisone in the hands, which helped for a short time, but then returned.  The patient was then diagnosed with an unknown autoimmune disorder and rheumatoid arthritis. The reporter consented to follow up.      Lab Comments: on an unknwn date, MRI of the cervical and thoracic spine and MRI were performed.
Age: 72.0
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Magnetic resonance imaging spinal normal, Musculoskeletal pain, Pain in extremity, Rheumatoid arthritis, X-ray normal
Clinical narrative: autoimmune reaction; rheumatoid arthritis diagnosis; knee joint pain/joints in body were painful; bilateral shoulder pain; joints in body were swollen; left arm soreness/right arm soreness/hand pain/finger pain; injection site pain; This case was reported by a consumer via call center representative and described the occurrence of autoimmune disorder in a 72-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 16th April 2018, the patient received the 1st dose of Shingrix (intramuscular). On 16th April 2018, 5 hrs after receiving Shingrix, the patient experienced injection site pain. On 17th April 2018, the patient experienced pain in arm. On 23rd April 2018, the patient experienced autoimmune disorder (serious criteria GSK medically significant), rheumatoid arthritis (serious criteria GSK medically significant), knee pain, shoulder pain and swollen joints. The patient was treated with hydrocortisone (Cortisone (Hydrocortisone)). On an unknown date, the outcome of the autoimmune disorder, rheumatoid arthritis, knee pain, pain in arm and shoulder pain were not recovered/not resolved and the outcome of the injection site pain was recovered/resolved and the outcome of the swollen joints was recovering/resolving.   It was unknown if the reporter considered the autoimmune disorder, rheumatoid arthritis, knee pain, injection site pain, pain in arm, shoulder pain and swollen joints to be related to Shingrix.  Additional details were provided as follows: The patient experienced injection site pain in the left upper arm. The next day after receiving Shingrix, the patient experienced arm soreness in both the left and right arms. One week after receiving Shingrix,  the patient began to experience bilateral shoulder pain.  The patient also experienced pain in hands and fingers. It was reported that all the joints in her body were swollen and painful. The patient experienced knee pain. The patient underwent an MRI of the cervical and thoracic spine which were negative. The patient was seen by a neurologist who reported there was no significant test abnormality. The patient was seen by an orthopedist and X-rays were negative. The patient was prescribed cortisone in the hands, which helped for a short time, but then returned.  The patient was then diagnosed with an unknown autoimmune disorder and rheumatoid arthritis. The reporter consented to follow up.      Lab Comments: on an unknwn date, MRI of the cervical and thoracic spine and MRI were performed.
Sex: F
Vaccine: FLU4, FLU3
Symptoms: Areflexia, Fall, Gait inability, Guillain-Barre syndrome, Hypoaesthesia
Clinical narrative: mild case of GB; arm  numbness, leg being completely numb; arm  tingling; Initial information received on 14-Oct-2019 regarding an unsolicited valid serious case received from a nurse.  This case involves a 35 years old female patient who experienced arm  numbness, leg being completely numb (Preferred term: Hypoaesthesia), arm tingling (Preferred term: Paraesthesia) and mild case of GB (Preferred term: Guillain-Barre syndrome), while she received vaccine INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED (Fluzone QIV).  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On 09 Oct 2019, the patient received a dose of suspect INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED batch number: UJ255AA and expiration date was unknown via unknown route in unknown administration site.  On 10 Oct 2019, 1 day after the vaccination, the patient experienced arm tingling and numbness (Hypoaesthesia and Paraesthesia). On 11 Oct 2019, patient fell out of bed due to leg being completely numb. Patient was admitted to the ICU for d 2 days. She was diagnosed with a mild case of GB (Guillain-Barre syndrome). This event was assessed as medically significant  No laboratory test was provided.  Final diagnosis was Guillain-Barre syndrome.   Corrective treatment was unknown.  The outcome was resolved on an unknown date for all the events.; Sender's Comments: This case concerns a 35 years old female patient who who presented with Guillain-Barre syndrome after vaccination with vaccine influenza quadrival a-b vaccine (Fluzone Qiv). The time to onset is compatible with the role of the vaccine. Additional information regarding patient's past medical history, condition at the time of vaccination, lab data excluding other predisposing etiologies would be needed for complete assessment of the case. Based upon the reported information, the role of the vaccine cannot be assessed.
Sex: F
Vaccine: FLU4, FLU3
Symptoms: Intensive care, Laboratory test, Lumbar puncture, Magnetic resonance imaging brain, Magnetic resonance imaging spinal
Clinical narrative: mild case of GB; arm  numbness, leg being completely numb; arm  tingling; Initial information received on 14-Oct-2019 regarding an unsolicited valid serious case received from a nurse.  This case involves a 35 years old female patient who experienced arm  numbness, leg being completely numb (Preferred term: Hypoaesthesia), arm tingling (Preferred term: Paraesthesia) and mild case of GB (Preferred term: Guillain-Barre syndrome), while she received vaccine INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED (Fluzone QIV).  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On 09 Oct 2019, the patient received a dose of suspect INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED batch number: UJ255AA and expiration date was unknown via unknown route in unknown administration site.  On 10 Oct 2019, 1 day after the vaccination, the patient experienced arm tingling and numbness (Hypoaesthesia and Paraesthesia). On 11 Oct 2019, patient fell out of bed due to leg being completely numb. Patient was admitted to the ICU for d 2 days. She was diagnosed with a mild case of GB (Guillain-Barre syndrome). This event was assessed as medically significant  No laboratory test was provided.  Final diagnosis was Guillain-Barre syndrome.   Corrective treatment was unknown.  The outcome was resolved on an unknown date for all the events.; Sender's Comments: This case concerns a 35 years old female patient who who presented with Guillain-Barre syndrome after vaccination with vaccine influenza quadrival a-b vaccine (Fluzone Qiv). The time to onset is compatible with the role of the vaccine. Additional information regarding patient's past medical history, condition at the time of vaccination, lab data excluding other predisposing etiologies would be needed for complete assessment of the case. Based upon the reported information, the role of the vaccine cannot be assessed.
Sex: F
Vaccine: FLU4, FLU3
Symptoms: Paraesthesia
Clinical narrative: mild case of GB; arm  numbness, leg being completely numb; arm  tingling; Initial information received on 14-Oct-2019 regarding an unsolicited valid serious case received from a nurse.  This case involves a 35 years old female patient who experienced arm  numbness, leg being completely numb (Preferred term: Hypoaesthesia), arm tingling (Preferred term: Paraesthesia) and mild case of GB (Preferred term: Guillain-Barre syndrome), while she received vaccine INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED (Fluzone QIV).  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On 09 Oct 2019, the patient received a dose of suspect INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED batch number: UJ255AA and expiration date was unknown via unknown route in unknown administration site.  On 10 Oct 2019, 1 day after the vaccination, the patient experienced arm tingling and numbness (Hypoaesthesia and Paraesthesia). On 11 Oct 2019, patient fell out of bed due to leg being completely numb. Patient was admitted to the ICU for d 2 days. She was diagnosed with a mild case of GB (Guillain-Barre syndrome). This event was assessed as medically significant  No laboratory test was provided.  Final diagnosis was Guillain-Barre syndrome.   Corrective treatment was unknown.  The outcome was resolved on an unknown date for all the events.; Sender's Comments: This case concerns a 35 years old female patient who who presented with Guillain-Barre syndrome after vaccination with vaccine influenza quadrival a-b vaccine (Fluzone Qiv). The time to onset is compatible with the role of the vaccine. Additional information regarding patient's past medical history, condition at the time of vaccination, lab data excluding other predisposing etiologies would be needed for complete assessment of the case. Based upon the reported information, the role of the vaccine cannot be assessed.
Sex: F
Vaccine: FLU4, FLU3
Symptoms: Fall, Guillain-Barre syndrome, Hypoaesthesia, Intensive care, Paraesthesia
Clinical narrative: mild case of GB; arm  numbness, leg being completely numb; arm  tingling; Initial information received on 14-Oct-2019 regarding an unsolicited valid serious case received from a nurse.  This case involves a 35 years old female patient who experienced arm  numbness, leg being completely numb (Preferred term: Hypoaesthesia), arm tingling (Preferred term: Paraesthesia) and mild case of GB (Preferred term: Guillain-Barre syndrome), while she received vaccine INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED (Fluzone QIV).  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On 09 Oct 2019, the patient received a dose of suspect INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED batch number: UJ255AA and expiration date was unknown via unknown route in unknown administration site.  On 10 Oct 2019, 1 day after the vaccination, the patient experienced arm tingling and numbness (Hypoaesthesia and Paraesthesia). On 11 Oct 2019, patient fell out of bed due to leg being completely numb. Patient was admitted to the ICU for d 2 days. She was diagnosed with a mild case of GB (Guillain-Barre syndrome). This event was assessed as medically significant  No laboratory test was provided.  Final diagnosis was Guillain-Barre syndrome.   Corrective treatment was unknown.  The outcome was resolved on an unknown date for all the events.; Sender's Comments: This case concerns a 35 years old female patient who who presented with Guillain-Barre syndrome after vaccination with vaccine influenza quadrival a-b vaccine (Fluzone Qiv). The time to onset is compatible with the role of the vaccine. Additional information regarding patient's past medical history, condition at the time of vaccination, lab data excluding other predisposing etiologies would be needed for complete assessment of the case. Based upon the reported information, the role of the vaccine cannot be assessed.
Age: 71.0
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Herpes zoster
Clinical narrative: shingles; itching/became incredibly itchy; burning; redness/nose turned bright red/whole area was red; dizzy; swelling/Her eyes became swollen; pimple; Her eyes became itchy; itchy/ forhead ithcy and whole area itchy; Red eye; This case was reported by a consumer via call center representative and described the occurrence of shingles in a 71-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. In November 2019, 2 weeks after receiving Shingrix, the patient experienced nasal itching, burning sensation, erythema, dizziness, eye swelling, pimples, eye pruritus, pruritus and eye red. On an unknown date, the patient experienced shingles. On an unknown date, the outcome of the shingles, nasal itching, eye pruritus and pruritus were recovering/resolving and the outcome of the burning sensation, erythema, dizziness and pimples were recovered/resolved and the outcome of the eye swelling was not recovered/not resolved and the outcome of the eye red was unknown.   It was unknown if the reporter considered the shingles, nasal itching, burning sensation, erythema, dizziness, eye swelling, pimples, eye pruritus, pruritus and eye red to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Shingrix either on the weekend of 26th October 2019 or 2nd November 2019.   It was reported that, a week prior of receiving Shingrix, she had a scratch biopsy on the tip of her nose and was healing fine. It was reported that, tip of her nose turned bright red with looked like a pimple.  It became incredibly itchy.  The red, itchy area then spread up her nose to her forehead and over both eyes.  Her eyes became swollen and itchy.  The area above her left eye was worsened. The whole area was red,burning and itchy. The patient was treated by a dermatologist who thinks it might be shingles. The patient also experienced some dizziness 4 days before the shingles presented. The reporter consented to follow up.
Age: 71.0
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Acne, Biopsy, Burning sensation, Dizziness, Erythema
Clinical narrative: shingles; itching/became incredibly itchy; burning; redness/nose turned bright red/whole area was red; dizzy; swelling/Her eyes became swollen; pimple; Her eyes became itchy; itchy/ forhead ithcy and whole area itchy; Red eye; This case was reported by a consumer via call center representative and described the occurrence of shingles in a 71-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. In November 2019, 2 weeks after receiving Shingrix, the patient experienced nasal itching, burning sensation, erythema, dizziness, eye swelling, pimples, eye pruritus, pruritus and eye red. On an unknown date, the patient experienced shingles. On an unknown date, the outcome of the shingles, nasal itching, eye pruritus and pruritus were recovering/resolving and the outcome of the burning sensation, erythema, dizziness and pimples were recovered/resolved and the outcome of the eye swelling was not recovered/not resolved and the outcome of the eye red was unknown.   It was unknown if the reporter considered the shingles, nasal itching, burning sensation, erythema, dizziness, eye swelling, pimples, eye pruritus, pruritus and eye red to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Shingrix either on the weekend of 26th October 2019 or 2nd November 2019.   It was reported that, a week prior of receiving Shingrix, she had a scratch biopsy on the tip of her nose and was healing fine. It was reported that, tip of her nose turned bright red with looked like a pimple.  It became incredibly itchy.  The red, itchy area then spread up her nose to her forehead and over both eyes.  Her eyes became swollen and itchy.  The area above her left eye was worsened. The whole area was red,burning and itchy. The patient was treated by a dermatologist who thinks it might be shingles. The patient also experienced some dizziness 4 days before the shingles presented. The reporter consented to follow up.
Age: 71.0
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Eye pruritus, Eye swelling, Herpes zoster, Nasal pruritus, Ocular hyperaemia
Clinical narrative: shingles; itching/became incredibly itchy; burning; redness/nose turned bright red/whole area was red; dizzy; swelling/Her eyes became swollen; pimple; Her eyes became itchy; itchy/ forhead ithcy and whole area itchy; Red eye; This case was reported by a consumer via call center representative and described the occurrence of shingles in a 71-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. In November 2019, 2 weeks after receiving Shingrix, the patient experienced nasal itching, burning sensation, erythema, dizziness, eye swelling, pimples, eye pruritus, pruritus and eye red. On an unknown date, the patient experienced shingles. On an unknown date, the outcome of the shingles, nasal itching, eye pruritus and pruritus were recovering/resolving and the outcome of the burning sensation, erythema, dizziness and pimples were recovered/resolved and the outcome of the eye swelling was not recovered/not resolved and the outcome of the eye red was unknown.   It was unknown if the reporter considered the shingles, nasal itching, burning sensation, erythema, dizziness, eye swelling, pimples, eye pruritus, pruritus and eye red to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Shingrix either on the weekend of 26th October 2019 or 2nd November 2019.   It was reported that, a week prior of receiving Shingrix, she had a scratch biopsy on the tip of her nose and was healing fine. It was reported that, tip of her nose turned bright red with looked like a pimple.  It became incredibly itchy.  The red, itchy area then spread up her nose to her forehead and over both eyes.  Her eyes became swollen and itchy.  The area above her left eye was worsened. The whole area was red,burning and itchy. The patient was treated by a dermatologist who thinks it might be shingles. The patient also experienced some dizziness 4 days before the shingles presented. The reporter consented to follow up.
Age: 71.0
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Pruritus
Clinical narrative: shingles; itching/became incredibly itchy; burning; redness/nose turned bright red/whole area was red; dizzy; swelling/Her eyes became swollen; pimple; Her eyes became itchy; itchy/ forhead ithcy and whole area itchy; Red eye; This case was reported by a consumer via call center representative and described the occurrence of shingles in a 71-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. In November 2019, 2 weeks after receiving Shingrix, the patient experienced nasal itching, burning sensation, erythema, dizziness, eye swelling, pimples, eye pruritus, pruritus and eye red. On an unknown date, the patient experienced shingles. On an unknown date, the outcome of the shingles, nasal itching, eye pruritus and pruritus were recovering/resolving and the outcome of the burning sensation, erythema, dizziness and pimples were recovered/resolved and the outcome of the eye swelling was not recovered/not resolved and the outcome of the eye red was unknown.   It was unknown if the reporter considered the shingles, nasal itching, burning sensation, erythema, dizziness, eye swelling, pimples, eye pruritus, pruritus and eye red to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Shingrix either on the weekend of 26th October 2019 or 2nd November 2019.   It was reported that, a week prior of receiving Shingrix, she had a scratch biopsy on the tip of her nose and was healing fine. It was reported that, tip of her nose turned bright red with looked like a pimple.  It became incredibly itchy.  The red, itchy area then spread up her nose to her forehead and over both eyes.  Her eyes became swollen and itchy.  The area above her left eye was worsened. The whole area was red,burning and itchy. The patient was treated by a dermatologist who thinks it might be shingles. The patient also experienced some dizziness 4 days before the shingles presented. The reporter consented to follow up.
Age: 56.0
Sex: F
Vaccine: FLU4, VARZOS, VARZOS
Symptoms: Chills, Herpes zoster, Malaise, Pain, Pyrexia
Clinical narrative: missed work; rash on her right lower torso; shingles; fever; chills; aches/Pain; didn't feel well; This case was reported by a pharmacist via call center representative and described the occurrence of shingles in a 56-year-old female patient who received Herpes zoster (Shingrix) (batch number 359Y3, expiry date 26th January 2022) for prophylaxis.   On 24th October 2019, the patient received the 1st dose of Shingrix. On 24th October 2019, less than a day after receiving Shingrix and an unknown time after starting Valtrex, the patient experienced fever, chills and pain. On 5th November 2019, the patient experienced shingles and rash. On an unknown date, the patient experienced feeling unwell and inability to work. The patient was treated with valaciclovir hydrochloride (Valtrex). On an unknown date, the outcome of the shingles, inability to work and rash were unknown and the outcome of the fever, chills, pain and feeling unwell were recovered/resolved.   It was unknown if the reporter considered the shingles, fever, chills, pain, feeling unwell, inability to work and rash to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient reported to pharmacist that she experienced fever, chills, aches and pain the night of the vaccination that lasted 12 hours. She was not feeling well for three days. She missed a day of work as well. On 5th November 2019,she had a rash on her right lower torso. She went to her physician that day and he did a skin test that was positive for shingles. She was given a prescription for Valtrex one gram three times daily for seven days. It was unknown how the shingles were at that time. The pharmacist did report the events to VAERS, however he submitted the report before she had the shingles episode. The reporter consented to follow up. This case has been linked with US2019209273, reported by the same reporter.
Age: 56.0
Sex: F
Vaccine: FLU4, VARZOS, VARZOS
Symptoms: Rash
Clinical narrative: missed work; rash on her right lower torso; shingles; fever; chills; aches/Pain; didn't feel well; This case was reported by a pharmacist via call center representative and described the occurrence of shingles in a 56-year-old female patient who received Herpes zoster (Shingrix) (batch number 359Y3, expiry date 26th January 2022) for prophylaxis.   On 24th October 2019, the patient received the 1st dose of Shingrix. On 24th October 2019, less than a day after receiving Shingrix and an unknown time after starting Valtrex, the patient experienced fever, chills and pain. On 5th November 2019, the patient experienced shingles and rash. On an unknown date, the patient experienced feeling unwell and inability to work. The patient was treated with valaciclovir hydrochloride (Valtrex). On an unknown date, the outcome of the shingles, inability to work and rash were unknown and the outcome of the fever, chills, pain and feeling unwell were recovered/resolved.   It was unknown if the reporter considered the shingles, fever, chills, pain, feeling unwell, inability to work and rash to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient reported to pharmacist that she experienced fever, chills, aches and pain the night of the vaccination that lasted 12 hours. She was not feeling well for three days. She missed a day of work as well. On 5th November 2019,she had a rash on her right lower torso. She went to her physician that day and he did a skin test that was positive for shingles. She was given a prescription for Valtrex one gram three times daily for seven days. It was unknown how the shingles were at that time. The pharmacist did report the events to VAERS, however he submitted the report before she had the shingles episode. The reporter consented to follow up. This case has been linked with US2019209273, reported by the same reporter.
Age: 56.0
Sex: F
Vaccine: FLU4, VARZOS, VARZOS
Symptoms: Chills, Herpes zoster, Impaired work ability, Malaise, Pain
Clinical narrative: missed work; rash on her right lower torso; shingles; fever; chills; aches/Pain; didn't feel well; This case was reported by a pharmacist via call center representative and described the occurrence of shingles in a 56-year-old female patient who received Herpes zoster (Shingrix) (batch number 359Y3, expiry date 26th January 2022) for prophylaxis.   On 24th October 2019, the patient received the 1st dose of Shingrix. On 24th October 2019, less than a day after receiving Shingrix and an unknown time after starting Valtrex, the patient experienced fever, chills and pain. On 5th November 2019, the patient experienced shingles and rash. On an unknown date, the patient experienced feeling unwell and inability to work. The patient was treated with valaciclovir hydrochloride (Valtrex). On an unknown date, the outcome of the shingles, inability to work and rash were unknown and the outcome of the fever, chills, pain and feeling unwell were recovered/resolved.   It was unknown if the reporter considered the shingles, fever, chills, pain, feeling unwell, inability to work and rash to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient reported to pharmacist that she experienced fever, chills, aches and pain the night of the vaccination that lasted 12 hours. She was not feeling well for three days. She missed a day of work as well. On 5th November 2019,she had a rash on her right lower torso. She went to her physician that day and he did a skin test that was positive for shingles. She was given a prescription for Valtrex one gram three times daily for seven days. It was unknown how the shingles were at that time. The pharmacist did report the events to VAERS, however he submitted the report before she had the shingles episode. The reporter consented to follow up. This case has been linked with US2019209273, reported by the same reporter.
Age: 56.0
Sex: F
Vaccine: FLU4, VARZOS, VARZOS
Symptoms: Pyrexia, Rash, Skin test positive
Clinical narrative: missed work; rash on her right lower torso; shingles; fever; chills; aches/Pain; didn't feel well; This case was reported by a pharmacist via call center representative and described the occurrence of shingles in a 56-year-old female patient who received Herpes zoster (Shingrix) (batch number 359Y3, expiry date 26th January 2022) for prophylaxis.   On 24th October 2019, the patient received the 1st dose of Shingrix. On 24th October 2019, less than a day after receiving Shingrix and an unknown time after starting Valtrex, the patient experienced fever, chills and pain. On 5th November 2019, the patient experienced shingles and rash. On an unknown date, the patient experienced feeling unwell and inability to work. The patient was treated with valaciclovir hydrochloride (Valtrex). On an unknown date, the outcome of the shingles, inability to work and rash were unknown and the outcome of the fever, chills, pain and feeling unwell were recovered/resolved.   It was unknown if the reporter considered the shingles, fever, chills, pain, feeling unwell, inability to work and rash to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient reported to pharmacist that she experienced fever, chills, aches and pain the night of the vaccination that lasted 12 hours. She was not feeling well for three days. She missed a day of work as well. On 5th November 2019,she had a rash on her right lower torso. She went to her physician that day and he did a skin test that was positive for shingles. She was given a prescription for Valtrex one gram three times daily for seven days. It was unknown how the shingles were at that time. The pharmacist did report the events to VAERS, however he submitted the report before she had the shingles episode. The reporter consented to follow up. This case has been linked with US2019209273, reported by the same reporter.
Age: 90.0
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Pain, Pruritus, Rash, Rash erythematous, Rash papular
Clinical narrative: red, raised rash with clear fluid all over her body / Scratchy and painful rash; red, raised rash with clear fluid all over her body / Scratchy and painful rash; red, raised rash with clear fluid all over her body / Scratchy and painful rash; Scratch; This case was reported by a pharmacist via call center representative and described the occurrence of red rash in a 90-year-old female patient who received Herpes zoster (Shingrix) (batch number 3E279, expiry date 19th March 2022) for prophylaxis.   On 2nd November 2019, the patient received the 1st dose of Shingrix (intramuscular). On 11th November 2019, 9 days after receiving Shingrix, the patient experienced red rash, blistery rash, papular rash and scratch. On an unknown date, the outcome of the red rash, blistery rash, papular rash and scratch were unknown.   It was unknown if the reporter considered the red rash, blistery rash, papular rash and scratch to be related to Shingrix.  Additional details were provided as follows: The patient received Shingrix in left deltoid. The patient received Shingrix and experienced a red, raised rash with clear fluid all over her body including her chest and hips. On the day of reporting, the rash was scratchy and painful when she itched it. The reporter consented to follow up.
Age: 90.0
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Secretion discharge
Clinical narrative: red, raised rash with clear fluid all over her body / Scratchy and painful rash; red, raised rash with clear fluid all over her body / Scratchy and painful rash; red, raised rash with clear fluid all over her body / Scratchy and painful rash; Scratch; This case was reported by a pharmacist via call center representative and described the occurrence of red rash in a 90-year-old female patient who received Herpes zoster (Shingrix) (batch number 3E279, expiry date 19th March 2022) for prophylaxis.   On 2nd November 2019, the patient received the 1st dose of Shingrix (intramuscular). On 11th November 2019, 9 days after receiving Shingrix, the patient experienced red rash, blistery rash, papular rash and scratch. On an unknown date, the outcome of the red rash, blistery rash, papular rash and scratch were unknown.   It was unknown if the reporter considered the red rash, blistery rash, papular rash and scratch to be related to Shingrix.  Additional details were provided as follows: The patient received Shingrix in left deltoid. The patient received Shingrix and experienced a red, raised rash with clear fluid all over her body including her chest and hips. On the day of reporting, the rash was scratchy and painful when she itched it. The reporter consented to follow up.
Age: 90.0
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Rash, Rash erythematous, Rash papular, Rash vesicular, Scratch
Clinical narrative: red, raised rash with clear fluid all over her body / Scratchy and painful rash; red, raised rash with clear fluid all over her body / Scratchy and painful rash; red, raised rash with clear fluid all over her body / Scratchy and painful rash; Scratch; This case was reported by a pharmacist via call center representative and described the occurrence of red rash in a 90-year-old female patient who received Herpes zoster (Shingrix) (batch number 3E279, expiry date 19th March 2022) for prophylaxis.   On 2nd November 2019, the patient received the 1st dose of Shingrix (intramuscular). On 11th November 2019, 9 days after receiving Shingrix, the patient experienced red rash, blistery rash, papular rash and scratch. On an unknown date, the outcome of the red rash, blistery rash, papular rash and scratch were unknown.   It was unknown if the reporter considered the red rash, blistery rash, papular rash and scratch to be related to Shingrix.  Additional details were provided as follows: The patient received Shingrix in left deltoid. The patient received Shingrix and experienced a red, raised rash with clear fluid all over her body including her chest and hips. On the day of reporting, the rash was scratchy and painful when she itched it. The reporter consented to follow up.